



## PRESS RELEASE

# Syngene International Commissions Dedicated R&D Center for Amgen Consolidates Ongoing Multi-discipline Research Collaboration

September 6<sup>th</sup>, 2016, Bangalore, India

Syngene International, one of Asia's largest R&D focused contract research organization, today announced the establishment in Bangalore, India, of an integrated, multi-disciplinary drug discovery and development center for Amgen, Inc. This center, named Syngene Amgen Research and Development Center (SARC), will be Syngene's fourth such exclusive R&D center. Syngene already operates dedicated R&D centers for Bristol-Myers Squibb, Abbott Nutrition and Baxter Inc.

The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines.

In addition to being customized to meet Amgen's functional requirements, the facility complies with the highest regulatory standards. Its design includes a range of environmentally-friendly features and flexible layouts, and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and "green" chemistry.

Commenting on the Syngene Amgen Research and Development Center, Jonathan Hunt, Chief Executive Officer, Syngene International, said, "We are delighted to announce the establishment of our dedicated R&D center for Amgen. Bringing together into one place, the range of activities we conduct on behalf of Amgen indicates the strategic nature of our relationship and also reflects the ability of Syngene's scientific teams to deliver world-class science towards our partners' R&D programs in both biotechnology and small molecule medicines."



# Syngene

Putting Science to Work

## PRESS RELEASE

Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.

### About Syngene

Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is one of Asia's largest Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. Syngene offers an integrated platform for R&D focused organizations to optimize their R&D investments and develop their novel molecules with a distinctive cost advantage. In FY2016, Syngene serviced 256 clients including 8 of the top 10 global pharma companies. For more details, visit: [www.syngeneintl.com](http://www.syngeneintl.com)

For further information please reach out to:

Investor Contact	Media Contact
Dinesh Iyer T: +91 80 2808 3912 M: +91 99866 91350 Fax: +91 80 2852 3423 E: <a href="mailto:dinesh.iyer@syngeneintl.com">dinesh.iyer@syngeneintl.com</a>	Sandeep Nair T: +91 80 2808 5476 M: +91 88843 67776 Fax: +91 80 2852 3423 E: <a href="mailto:sandeep.nair@syngeneintl.com">sandeep.nair@syngeneintl.com</a>